Barrington analyst Michael Petusky lowered the firm’s price target on Anika Therapeutics (ANIK) to $15 from $19 and keeps an Outperform rating on the shares, citing “incrementally negative Hyalofast news” for the firm’s lowered target. However, shares are “meaningfully undervalued and trading near max skepticism after yesterday’s 27% decline,” the analyst argues.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIK: